NCT00568646

Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer

A Phase 2 Study of Oral MKC 1, Administered Twice Daily for 14 Consecutive Days in a 28-Day Cycle, in Patients With Unresectable or Metastatic Pancreatic Cancer Who Have Failed at Least One Prior Chemotherapy Regimen in Either the Neoadjuvant, Adjuvant, or First-line Metastatic Setting

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 33 (estimated)
• Sponsor: CASI Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To determine the antitumor activity of MKC-1 in patients with unresectable or metastatic pancreatic cancer who have failed at least one prior chemotherapy regimen in either the neoadjuvant, adjuvant, or first-line metastatic setting

Conditions

• Pancreatic Cancer

Interventions

Type	Name	Description
DRUG	MKC-1	Oral MKC-1 capsules, administered twice daily, for 14 consecutive days, in a 28-day cycles

Timeline

• Start date: 2007-11-01
• Primary completion: 2009-04-01
• Completion: 2009-05-01
• First posted: 2007-12-06
• Last updated: 2011-08-04

Locations

2 sites across 1 country: United States